Salsalate has no effect on insulin secretion but decreases insulin clearance: a randomized, placebo‐controlled trial in subjects without diabetes

Publisher： John Wiley & Sons Inc

E-ISSN： 1463-1326|17|6|608-612

ISSN： 1462-8902

Source： DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol.17, Iss.6, 2015-06, pp. : 608-612

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Efficacy and safety of liraglutide versus placebo added to basal insulin analogues (with or without metformin) in patients with type 2 diabetes: a randomized, placebo‐controlled trial

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 17, Iss. 11, 2015-11 ,pp. : 1056-1064

John Wiley & Sons Inc

Access to resources Recommend Favorite

Empagliflozin as adjunct to insulin in patients with type 1 diabetes: a 4‐week, randomized, placebo‐controlled trial (EASE‐1)

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 1462-8902, Iss. 10, 2015-10 ,pp. : 928-935

John Wiley & Sons Inc

Access to resources Recommend Favorite

Empagliflozin as adjunct to insulin in patients with type 1 diabetes: a 4‐week, randomized, placebo‐controlled trial (EASE‐1)

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 17, Iss. 10, 2015-10 ,pp. : 928-935

John Wiley & Sons Inc

Access to resources Recommend Favorite

Metformin and β‐cell function in insulin‐treated patients with type 2 diabetes: A randomized placebo‐controlled 4.3‐year trial

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 20, Iss. 3, 2018-03 ,pp. : 730-733

John Wiley & Sons Inc

Access to resources Recommend Favorite

Impact of empagliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: a 78‐week randomized, double‐blind, placebo‐controlled trial

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 17, Iss. 10, 2015-10 ,pp. : 936-948

John Wiley & Sons Inc

Access to resources Recommend Favorite